Alimera SciencesALIM
ALIM
Delisted
ALIM was delisted on the 17th of September, 2024.
About: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Employees: 158
Financial journalist opinion
Positive
Zacks Investment Research
3 months ago
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
3 months ago
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patie.
Neutral
Business Wire
3 months ago
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
ATLANTA--(BUSINESS WIRE)--Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced that it has filed a lawsuit in the Delaware Court of Chancery (the “Court”) to compel ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) to fulfill its contractual obligation to close the transaction contemplated by the companies' previo.
Neutral
Business Wire
4 months ago
ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon th.
Negative
Zacks Investment Research
4 months ago
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Alimera Sciences Reports Second Quarter 2024 Results
ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).
Neutral
GlobeNewsWire
4 months ago
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
Neutral
PRNewsWire
4 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
Neutral
GlobeNewsWire
5 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
Neutral
PRNewsWire
5 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
NEW YORK , July 2, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
Charts implemented using Lightweight Charts™